Revenue
2022
2023
2024
2025
Aprea Therapeutics, Inc. (APRE)
Price$0.7999Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2023
2024
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $285,759 | $1.5M | $583,231 | $0 | — | — | — | — | — |
| Research & development | $7.0M | $9.4M | $7.6M | $16.4M | $23.9M | $37.9M | $21.0M | $14.2M | $13.4M |
| Operating expenses | $13.5M | $15.8M | $16.1M | $113.4M | $37.4M | $52.8M | $29.5M | $16.5M | $15.9M |
| Operating income | −$13.2M | −$14.3M | −$15.5M | −$113.4M | −$37.4M | — | — | — | — |
| Operating margin | −4,631.12% | −953.00% | −2,652.80% | — | — | — | — | — | — |
| EBITDA | −$13.2M | −$14.3M | −$15.5M | −$113.4M | −$37.4M | — | — | — | — |
| EBITDA margin | −4,623.52% | −951.52% | −2,651.59% | — | — | — | — | — | — |
| Net income | −$12.6M | −$13.0M | −$14.3M | −$112.7M | −$37.1M | −$53.5M | −$28.1M | −$15.5M | −$15.2M |
| Net profit margin | −4,409.16% | −862.43% | −2,449.59% | — | — | — | — | — | — |
| Basic EPSper basic share | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$93.40 | -$269.00 | -$263.40 |
| Diluted EPSper diluted share | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$93.40 | -$269.00 | -$263.40 |
Owners
Reported shareholders
8.20%of listed shares
AIGH Capital Management LLC1.02M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
AIGH Capital Management LLC | 8.20%1.02M shares |
Nantahala Capital Management, LLC | 3.32%411.52K shares |
Gilad Oren | ≈3.19%395.7K shares |
Vestal Point Capital, LP | 2.82%350K shares |
SPHERA FUNDS MANAGEMENT LTD. | 2.18%270K shares |
Duey Marc | ≈2.10%259.89K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.85%105.8K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.60%74.87K shares |
CITADEL ADVISORS LLC | 0.47%58.6K shares |
Seizinger Bernd R. | ≈0.39%48.91K shares |
BNP PARIBAS FINANCIAL MARKETS | 0.36%45.21K shares |
DIADEMA PARTNERS LP | 0.36%44.91K shares |
Hamill John P. | ≈0.35%43.53K shares |
VANGUARD FIDUCIARY TRUST CO | 0.31%38.46K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.28%34.94K shares |
MORGAN STANLEY | 0.21%25.83K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.18%22.88K shares |
Pamukcu Rifat | ≈0.18%22.69K shares |
LPL Financial LLC | 0.13%16.05K shares |
HighTower Advisors, LLC | 0.11%13.86K shares |
Percentages use 12.39M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 31, 2026Form 4 | Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | BuyCommon Warrant · derivative | 31.0K | — | — | 31.0K |
| Mar 31, 2026Form 4 | Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | BuyPre-Funded Warrant · derivative | 31.0K | $0.81 | $25.1K | 31.0K |
| Mar 31, 2026Form 4 | Peters RichardDirector | BuyCommon Warrant · derivative | 123.9K | — | — | 123.9K |
| Mar 31, 2026Form 4 | Peters RichardDirector | BuyPre-Funded Warrant · derivative | 123.9K | $0.81 | $100.4K | 123.9K |
| Jan 30, 2026Form 4 | Gilad OrenPresident/CEO | BuyCommon Stock | 28.1K | $0.89 | $25.0K | 373.7K |